Myles Ward

Baxter Healthcare Corp. develops, manufactures, and distributes hospital supplies and medical technologies. It distributes medical treatment options for conditions such as hemophilia, immune disorders, kidney disease, cancer, and trauma. The company was founded on June 21, 1967 and is headquartered in Deerfield, IL.

XL TechGroup, Inc. invests in the biotech, ecotech and medtech sectors. It also develops and commercializes proprietary insecticide and parasiticide products including non-toxic, pesticides, and anti-parasitic compounds for use in agriculture, horticulture, functional foods, healthcare, and veterinary applications. The firm involves in commercializing new technologies to grow and harvest oil from algae, an alternative to petroleum oil. The company was founded in 1993 and is located in Melbourne, FL.

The Royal Pharmaceutical Society of Great Britain provides expertise and support to its member pharmacists. The private company is based in Great Britain. Alex MacKinnon has been the CEO of the British company since 2010.

National Health Service provides health care services. It offers hospital services, family doctors, dentists, opticians and pharmacists and local authority health services, community nursing and health care services. The company was founded by Aneurin Bevan on July 5, 1948 and is headquartered in London, the United Kingdom.

MedPharm Ltd. provides pharmaceutical research and development services for dermatological, nail, eye, airway, mucosal membrane, and transdermal products. Its drug delivery technologies include MedSpray, a patch-in-a-can aerosol technology for drug delivery in the form of a film to topical/mucosal membranes for immediate or sustained/extended delivery. The company was founded by Andrew G. Muddle in August 1999 and is headquartered in Guildford, the United Kingdom.

Countrywest Trading Ltd. supplies animal feed. The company was founded in 1919 and is headquartered in Kingsbridge, GB.

Apitope Technology (Bristol) Ltd. is a European biotech company developing therapeutic vaccines for treating autoimmune and allergic diseases, including multiple sclerosis, Type 1 diabetes, Graves' disease, allergies and organ transplant rejection. The team at Apitope is developing potential therapies intended to selectively treat the underlying cause of a range of autoimmune diseases rather than simply treat the disease symptoms or non-specifically suppress the whole immune system. Apitope's approach is based on well-established scientific evidence published in leading scientific journals showing that soluble, synthetic peptides can selectively suppress abnormal immune responses and reinstate the normal immune balance and thereby, tolerance. The firm's strategy is to position itself as a significant player in the therapeutic peptide space and make it a partner of choice for pharmaceutical companies keen to develop disease modifiers for autoimmune conditions. It has a highly experienced senior management team, with a proven track record in discovering and developing innovative compounds. The company's lead product candidate is under investigation for the potential treatment of multiple sclerosis and is currently in Phase I clinical development. It is partnered with Merck-Serono (a division of Merck KGaA, Darmstadt, Germany), one of the leading companies in the development and marketing of MS therapies.

Spark Therapeutics Ireland Ltd. develops new gene medicines to treat autosomal dominant genetic diseases. Its product RhoNova, is designed for the treatment of patients with rhodopsin linked autosomal dominant retinitis pigmentosa, a debilitating, progressive form of inherited blindness resulting from a diverse array of mutations in the RHO gene. The company was founded by Jane G. Farrar, Paul Kenna, and Gearóid Tuohy and is headquartered in Dublin, Ireland.

Ziggus Holdings Ltd. operates cattle and sheep farms. Geoffrey Nicholas Vernon has been the CEO of the British company since 1998.

Veryan Medical Ltd. develops and commercializes novel vascular stent technology. The firm's products are designed to clinical performance and bio-mechanical performance of stented vessels. The company was founded by Colin G. Caro, Charles Richard Taylor and Paul Burke Gilson in 2003 and is headquartered in Oxford, the United Kingdom.